

## News Release

### TAP Technology Originators nominated for title of European Inventor of the Year 2008

#### *Award created by the European Commission and European Patent Office*

**Boston, 11<sup>th</sup> April 2008** - Cellzome Inc. is pleased to announce the nominations of Dr Bertrand Séraphin and Dr Guillaume Rigaut for the title of European Inventor of the Year 2008 by the European Commission and the European Patent Office.

Drs Bertrand Séraphin and Guillaume Rigaut are the inventors of the Tandem Affinity Purification (TAP) technology which is the proprietary method for pathway mapping owned by the European Molecular Biology Laboratory in Heidelberg, Germany and licensed exclusively to Cellzome. TAP technology is used for the isolation of protein complexes which constitute cellular pathways, and it is ideally suited for combination with Cellzome's sensitive mass spectrometric analysis to generate reliable and reproducible data. It allows the purification of complexes under close to physiological conditions and is broadly applicable to a wide range of proteins from different subcellular compartments.

The nominations have been made by a prestigious panel of experts from industry, business and research, and the award is a distinction for inventors in any technical field who have made an outstanding contribution to innovation in Europe. This year 12 inventions have been nominated and all have been patented. Dr Séraphin and Dr Rigaut are one of the three nominees in the category 'Small and Medium-Sized Enterprises/Research' for their patent in respect of the method for purifying biomolecule and protein complexes.

The final winners will be announced at an awards ceremony in Ljubljana, Slovenia on 6 May 2008, with prizes being given by Danilo Türk, President of the Republic of Slovenia.

Tim Edwards, CEO of Cellzome said: "On behalf of everyone at Cellzome, I offer my congratulations to Bertrand and Guillaume on their nominations for this prestigious award."

#### **About Cellzome Inc.**

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by *Kinobeads*<sup>TM</sup>, a proprietary technology for screening and profiling of kinases in relevant cells and tissues.

Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, initially for asthma and allergic rhinitis. Cellzome is applying its distinctive *Kinobeads*<sup>TM</sup> technology to the discovery and development of novel, selective kinase inhibitors targeting key inflammatory mediators in immune receptor signaling and chemotaxis, including PI3Kgamma and Zap-70.

The Company has collaborations with Novartis on the discovery of target-lead pairs in a variety of disease areas, and with Johnson & Johnson for the discovery of novel medicines for the treatment of Alzheimer's disease.

Cellzome's holding company is domiciled in the US and it employs about 85 people at its two operating subsidiaries in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: [www.cellzome.com](http://www.cellzome.com).

#### **For further information please contact:**

**Cellzome AG**  
Tim Edwards  
Chief Executive Officer  
Tel: +49 (0) 6221-137 57-100  
[press@cellzome.com](mailto:press@cellzome.com)

**Media Contact**  
**Hogarth Partnership**  
John Olsen/Melanie Toyne-Sewell  
Tel: +44 (0) 207 357 9477  
[mtoyne-sewell@hogarthpr.co.uk](mailto:mtoyne-sewell@hogarthpr.co.uk)